Clinical Trials on Monomorphic Post-Transplant Lymphoproliferative Disorder in Japan

Total 393 results

GlaxoSmithKline

Recruiting

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM5)

Multiple Myeloma

United States, Australia, France, Japan, Netherlands, Poland, Spain, Sweden, Greece, Canada, Korea, Republic of, Germany, Brazil, Israel, Mexico, Norway, Russian Federation
Eli Lilly and Company

Completed

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Non Hodgkin Lymphoma

United States, China, Spain, Poland, Taiwan, Belgium, Japan, Germany, Puerto Rico, Australia, France, Sweden, Greece, Italy, India, Czechia, United Kingdom, Canada, Korea, Republic of, Mexico, Denmark, Portugal, Finland, Brazil, Hungary
TeneoOne Inc.

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia, Germany, Japan, Spain, United States, Italy, Poland
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Adult T-cell Leukemia/Lymphoma

Japan
Bayer

Terminated

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4)

Lymphoma, Non-Hodgkin

United States, Hungary, China, Belgium, Korea, Republic of, France, Australia, Russian Federation, Taiwan, Denmark, Japan, United Kingdom, Spain, South Africa, Turkey, Romania, Singapore, Israel, Ireland, Canada, Poland, Greece, Cze... and more
Genmab
AbbVie

Recruiting

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3)

Diffuse Large B-Cell Lymphoma

France, Korea, Republic of, Spain, Belgium, Japan, Germany, Czechia, United Kingdom, Italy, Austria, United States, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)

Multiple Myeloma

United States, Netherlands, Belgium, Korea, Republic of, United Kingdom, Sweden, Denmark, Italy, Japan, Germany, France, Spain, Australia, Israel, Poland, Greece
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Churg-Strauss Syndrome | Eosinophilic Granulomatosis With Polyangiitis

United States, Japan
AbbVie
Genentech, Inc.

Completed

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Japan
Janssen Research & Development, LLC
Pharmacyclics LLC.

Enrolling by invitation

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Follicular Lymphoma | Chronic Graft Versus Host Disease | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma

United States, Spain, United Kingdom, Israel, Canada, Belgium, Poland, China, Japan, France, Australia, Russian Federation, Turkey, Sweden, Italy, Mexico, Czechia, Korea, Republic of, Ukraine, Brazil, Hungary, Portugal, Argentina, Col... and more
Novartis Pharmaceuticals

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (MASter-1)

NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

United States, Canada, United Kingdom, Turkey, Spain, France, Japan, Czechia, Italy
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (SELENE)

Lymphoma

United States, France, Ukraine, United Kingdom, China, Germany, Spain, Argentina, Belgium, Israel, Russian Federation, Turkey, Japan, Australia, Sweden, Korea, Republic of, Brazil, Puerto Rico, Poland
Hoffmann-La Roche
Institute of Cancer Research, United Kingdom; German Low Grade Lymphoma Study...

Completed

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Non-Hodgkin's Lymphoma

Italy, Belgium, Canada, United Kingdom, Australia, China, Germany, United States, Russian Federation, Spain, Taiwan, Israel, Czechia, Hungary, Japan, France, Finland, Sweden
Amgen

Active, not recruiting

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia

United States, Australia, Japan, Germany, Canada
Amgen

Recruiting

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

B Cell Precursor Acute Lymphoblastic Leukemia

Japan, Australia, Spain, United States, Italy, Germany, France, Turkey, Canada, Netherlands, Austria
Pfizer

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)

Multiple Myeloma

Japan, Taiwan, Canada, Spain, Australia, Italy, Czechia, Korea, Republic of, France, Greece, Israel, Poland, Germany
Stichting European Myeloma Network
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Multiple Myeloma

Netherlands, United States, Spain, Belgium, France, Italy, Germany, Japan, Canada, Australia, Sweden, Israel, United Kingdom, Czechia, Greece, Switzerland, Norway
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET)

Diffuse Large B-cell Lymphoma (DLBCL)

United States, Japan, Australia, Italy, Canada, Germany, Norway, Netherlands, France, Austria
Novartis Pharmaceuticals

Terminated

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy (A+B)

Lymphoma, Follicular

United States, Belgium, Italy, Hong Kong, Austria, Germany, Japan, Russian Federation, United Kingdom, Canada, Slovakia, Poland, Ukraine, Puerto Rico, Greece, France, Argentina
Janssen Research & Development, LLC

Approved for marketing

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Multiple Myeloma

United States, United Kingdom, Spain, Brazil, Russian Federation, Japan
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Germany, Korea, Republic of, Belgium, Israel, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Japan, Czechia, Brazil, Netherlands, Poland, Portugal, Switzerland, Norway, Greece, China, Canada
Celgene

Active, not recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Spain, United Kingdom
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | AML | Myelodysplastic Syndrome | MDS | Non-Hodgkins Lymphoma | NHL

United States, Australia, Italy, France, Greece, Japan
Takeda
Seagen Inc.

Active, not recruiting

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, France, Italy, Poland, United Kingdom, Belgium, Hong Kong, Taiwan, Spain, South Africa, Turkey, Canada, Denmark, Korea, Republic of, Australia, Russian Federation, Brazil, Hungary, Norway, Czechia, Japan
Hoffmann-La Roche

Recruiting

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO)

Non-Hodgkin Lymphoma

United States, Korea, Republic of, China, Mexico, Japan, Brazil, Argentina, Thailand, Canada, Peru, Turkey, Russian Federation, Israel, New Zealand
AbbVie

Active, not recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

Japan
Celgene

Completed

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) (AUGMENT)

Lymphoma, Non-Hodgkin

United States, Spain, China, Belgium, France, United Kingdom, Israel, Turkey, Russian Federation, Italy, Brazil, Czechia, Portugal, Germany, Japan, Poland, Puerto Rico
Novartis Pharmaceuticals

Active, not recruiting

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Non-Hodgkin Lymphoma

Spain, Taiwan, Australia, Belgium, Germany, Italy, Singapore, Austria, France, Switzerland, Hong Kong, United States, Netherlands, Norway, United Kingdom, Brazil, China, Japan
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)

Hematological Malignancies

United States, Belgium, Korea, Republic of, China, Germany, Israel, Netherlands, Japan, Spain, France, Poland
Janssen Research & Development, LLC

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Multiple Myeloma

United States, Korea, Republic of, Czechia, Israel, Switzerland, Belgium, United Kingdom, Japan, Canada, Spain, Sweden, Germany, Australia, Netherlands, France, Argentina, Brazil, Denmark, Greece, Poland, Ireland, Hungary, Portugal, F... and more
Janssen Research & Development, LLC

Completed

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States, Czechia, Israel, Italy, Korea, Republic of, Brazil, United Kingdom, Japan, Taiwan, Australia, Poland, Spain, France, Russian Federation, Sweden, Ukraine, Greece
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Multiple Myeloma

Canada, United States, Israel, Czechia, Turkey, Germany, United Kingdom, Netherlands, Japan, France, Poland, Spain, Brazil
Genmab
AbbVie

Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL (EPCORE™ NHL-3)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

Japan
Pfizer
UCB Pharma

Terminated

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Lymphoma, Non-Hodgkin

Canada, United States, Spain, France, Singapore, Taiwan, Japan, Ireland, Belgium, United Kingdom, Germany, Slovakia, Thailand, Croatia, Czechia, Russian Federation, India, Sweden, Poland, Bulgaria, Hungary, Lithuania, Mexico, Puerto Rico and more
Sanofi

Active, not recruiting

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)

Plasma Cell Myeloma

France, United States, Australia, Brazil, Canada, Czechia, Greece, Hungary, Italy, Japan, Korea, Republic of, New Zealand, Russian Federation, Spain, Turkey, United Kingdom
Sandoz
Novartis Pharmaceuticals

Completed

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) (ASSIST_FL)

Follicular Lymphoma

Russian Federation, Netherlands, Peru, United Kingdom, Romania, Brazil, Malaysia, Spain, India, Italy, Bulgaria, Poland, South Africa, Japan, Argentina, Australia, Austria, Colombia, France, Germany, Greece, Hungary, Ireland, Israel, Po... and more
GlaxoSmithKline

Recruiting

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)

Multiple Myeloma

China, Korea, Republic of, Australia, Italy, Spain, United States, Brazil, Czechia, France, Germany, Greece, Israel, Japan, New Zealand, Poland, Russian Federation, Turkey, United Kingdom
GlaxoSmithKline

Active, not recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Multiple Myeloma

United States, Australia, Spain, Bulgaria, Poland, Belgium, France, Germany, Italy, Hungary, United Kingdom, Greece, Russian Federation, Brazil, China, Korea, Republic of, Japan, Canada, Netherlands
Takeda

Active, not recruiting

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma (iinnovate-1)

Multiple Myeloma

United States, Spain, Canada, Korea, Republic of, Taiwan, China, Italy, Germany, Israel, France, United Kingdom, Greece, Japan, Norway, Puerto Rico, Turkey
Eisai Co., Ltd.

Recruiting

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Lymphoma, Follicular

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Korea, Republic of, Israel, Japan, Germany, Spain, Australia, China, France, United Kingdom, Greece, Italy
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Lymphoma, B-Cell

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Japan, Canada, Netherlands, Denmark, Sweden, Korea, Republic of, Russian Federation, Greece
4SC AG

Active, not recruiting

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Sezary Syndrome

Austria, Spain, Germany, United Kingdom, France, Belgium, Japan, Switzerland, Italy, Poland, Netherlands, Greece
Amgen

Completed

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma (ARROW)

Multiple Myeloma

Canada, Denmark, Finland, France, Italy, Spain, Sweden, United Kingdom, Czechia, Poland, United States, Belgium, Hungary, New Zealand, Australia, Germany, Japan, Greece, Norway, Romania
Novartis Pharmaceuticals
Bristol-Myers Squibb

Recruiting

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

United States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, Denmark, United States, Spain, Australia, Japan, France, Korea, Republic of, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, United Kingdom, Czechia, Germany, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more

Clinical Trials on Monomorphic Post-Transplant Lymphoproliferative Disorder in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations